On 2 April 2026, the UK Government published text memorializing its agreement with the U.S. in relation to pharmaceutical pricing. The UK now refers to this as an “arrangement” (“U.S.-UK Pharmaceutical Pricing Arrangement”). Our blog post from December discussed the in-principle heads of terms for the deal announced in December 2025, with various details marked
Latest Post
More Posts
European Commission Adopts Proposal for the Biotech Act
European Biotech Act: Potential new extension for supplementary protection certificates (SPCs) for ATMPs and biotechnology medicines
The Proposed EU Biotech Act Aims to Accelerate and Streamline Procedures for the Approval of Clinical Trials and Combined Studies
EU Announces Political Agreement on Pharma Law Review
Landmark UK-US Pharmaceutical Deal
The Updated NHS Commercial Framework for New Medicines
Re-Launch of UK’s Innovative Licensing and Access Pathway (“ILAP”)
MHRA Consultation on Individualised mRNA Cancer Immunotherapies – Unique opportunity for a streamlined risk based regulatory framework?
The Covington European Life Sciences Symposium 2025
Connect: http://www.cov.com/gcastle
Subscribe: Subscribe via RSS